GlassScriptPhysician profile
Breeann Gilmore
NPI 1679941884
$8,012.37
in general payments reported to CMS, 2019-2025
19 companies · $955 in 2025
The $955 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,560 · 2022: $1,808 · 2023: $1,438 · 2024: $1,252 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,540 · Education: $76.99 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,540.27 |
| Education | $76.99 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,445.34 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,870.82 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,423.60 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $459.37 | 2021-2024 | Gattex |
| Ironwood Pharmaceuticals, INC | $292.61 | 2021-2024 | Linzess |
| Ardelyx, INC. | $244.59 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $175.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $142.07 | 2021-2025 | |
| Gilead Sciences, INC. | $131.83 | 2024-2025 | |
| Redhill Biopharma INC. | $109.86 | 2021-2024 | Talicia |
| Regeneron Healthcare Solutions, INC. | $108.30 | 2022-2023 | Dupixent |
| Celgene Corporation | $106.13 | 2022-2023 | Zeposia |
| Evoke Pharma, INC. | $103.84 | 2024-2025 | |
| Braintree Laboratories, INC. | $98.52 | 2021-2023 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $92.80 | 2024-2025 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $77.80 | 2021-2023 | |
| Genzyme Corporation | $56.78 | 2022 | |
| Ferring Pharmaceuticals INC. | $44.61 | 2022-2023 | Clenpiq, Cimzia |
| Merck Sharp & Dohme LLC | $28.44 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breeann Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.